BIO-TECHNE Corp vs Texas Instruments Incorporated — how do they compare? BIO-TECHNE Corp trades at $72.44 (market cap $11.36B), while Texas Instruments Incorporated trades at $283.94 (market cap $263.20B). The key difference: Texas Instruments Incorporated is far larger — about 23.2× BIO-TECHNE Corp's market cap, and Texas Instruments Incorporated pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 64 Days and Texas Instruments Incorporated for 76 Days on average.
| TECH | TXN | |
|---|---|---|
Market Cap | $11.36B | $263.20B |
Volume | 5,390,331 | 5,850,256 |
Sector | Health | Technology |
52-Week High | $72.61 | $332.35 |
52-Week Low | $43.31 | $153.33 |
Typical Hold Time | 64 Days | 76 Days |
Enterprise Value | $11.39B | $270.25B |
Dividend Yield | 0.44% | 2.11% |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Texas Instruments (TXN) trades at $288.94, down 2.82% on the day, amid a broader semiconductor sell-off. The stock maintains a bullish technical outlook with strong moving average signals and key support at $286. Fundamentally, revenue and earnings are recovering, with Q2 2026 EPS beating expectations at $2.14 versus $1.91, driven by data center sales growth and margin expansion. The company's net income margin stands at 31.11%, with robust cash flow from operations of $7.15 billion in 2025.
The outlook for TXN is positive, supported by accelerating data center demand, AI infrastructure investments, and a consensus price target of $325 implying 12% upside. Risks include premium valuation with a P/E of 43.8 and rising debt-to-asset ratio of 40.61% in 2025. Analyst sentiment is bullish with 47.69% buy ratings, though competitive pressures and cyclical semiconductor demand pose headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →